These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 26373980

  • 1. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q, Inostroza M, Rico Juri JM, Goffette P, Lerut J.
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [Abstract] [Full Text] [Related]

  • 2. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F, Marciano S, Anders M, Orozco Ganem F, Zerega A, Cagliani J, Andriani O, de Santibañes E, Gil O, Podestá LG, McCormack L, Gadano A, Silva M.
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [Abstract] [Full Text] [Related]

  • 3. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
    Xiao GQ, Yang JY, Yan LN.
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
    [Abstract] [Full Text] [Related]

  • 4. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U, Italian Liver Cancer Group.
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [Abstract] [Full Text] [Related]

  • 5. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY.
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [Abstract] [Full Text] [Related]

  • 6. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
    Shim JH, Lee HC, Han S, Kang HJ, Yu E, Lee SG.
    Liver Transpl; 2013 Mar; 19(3):336-45. PubMed ID: 23203386
    [Abstract] [Full Text] [Related]

  • 7. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K.
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [Abstract] [Full Text] [Related]

  • 8. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M, Tan W, Yang X, Zhuo J, Lin Z, Cen B, Lian Z, Li H, Lu D, Wei X, Zheng S, Xu X.
    Cancer Biomark; 2020 Jan; 29(2):197-206. PubMed ID: 32623388
    [Abstract] [Full Text] [Related]

  • 9. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma.
    Decaens T, Roudot-Thoraval F, Badran H, Wolf P, Durand F, Adam R, Boillot O, Vanlemmens C, Gugenheim J, Dharancy S, Bernard PH, Boudjema K, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Hilleret MN, Chazouillères O, Cherqui D, Mallat A, Duvoux C.
    Liver Int; 2011 Jul; 31(6):792-801. PubMed ID: 21645209
    [Abstract] [Full Text] [Related]

  • 10. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D, Liver Transplantation French Study Group.
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [Abstract] [Full Text] [Related]

  • 11. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH, Kim EY, Hong TH, You YK, Kim DG.
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [Abstract] [Full Text] [Related]

  • 12. How to select suitable hepatocellular carcinoma for liver transplantation by preoperative neutrophil-lymphocyte ratio.
    Xiao GQ, Yan L, Yang J.
    Hepatogastroenterology; 2014 Oct; 61(135):2077-83. PubMed ID: 25713913
    [Abstract] [Full Text] [Related]

  • 13. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW.
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [Abstract] [Full Text] [Related]

  • 14. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.
    Pang Q, Zhang JY, Xu XS, Song SD, Qu K, Chen W, Zhou YY, Miao RC, Liu SS, Dong YF, Liu C.
    World J Gastroenterol; 2015 May 14; 21(18):5607-21. PubMed ID: 25987786
    [Abstract] [Full Text] [Related]

  • 15. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY.
    Liver Transpl; 2014 Aug 14; 20(8):945-51. PubMed ID: 24797281
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.
    Han JH, Kim DG, Na GH, Kim EY, Lee SH, Hong TH, You YK.
    World J Gastroenterol; 2014 Dec 07; 20(45):17132-40. PubMed ID: 25493027
    [Abstract] [Full Text] [Related]

  • 17. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q, Shang L, Zang Y, Chen X, Zhang L, Wang Y, Wang L, Liu Y, Mao S, Shen Z.
    Eur J Gastroenterol Hepatol; 2014 May 07; 26(5):544-52. PubMed ID: 24614696
    [Abstract] [Full Text] [Related]

  • 18. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y.
    Hepatobiliary Pancreat Dis Int; 2012 Jun 07; 11(3):256-61. PubMed ID: 22672818
    [Abstract] [Full Text] [Related]

  • 19. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN.
    Transplant Proc; 2011 Dec 07; 43(10):3813-8. PubMed ID: 22172852
    [Abstract] [Full Text] [Related]

  • 20. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L, Liao A, Yan L, Li B, Zhu W, Wen T.
    Hepatogastroenterology; 2014 May 07; 61(131):747-51. PubMed ID: 26176068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.